PDF DatasheetHuman and Rat Anti-VLDL-Receptor Antibody Product Attributes
Species: Human and Rat
Tested Applications: Immunohistochemistry (IHC).
Clonality: Monoclonal
Anti-VLDL-Receptor Antibody Clone: VLDLR/1337
Clone VLDLR/1337 Host and Isotype: Mouse IgG1
Anti-Human and Rat VLDL-Receptor Positive Control Sample: HeLa or U-251 cells. Pancreas, Cerebellum, Heart or Skeletal Muscle.
Cellular Localization of Antibody Cytoplasmic
Buffer and Stabilizer: 10mM PBS with 0.05% BSA and 0.05% Azide
Antibody Concentration: 200 ug/ml
Antibody Purification Method:Protein A/G Purified
Immunogen: Recombinant human VLDLR fragment from c-terminal
Storage Conditions: Store at 2 to 8° C (refrigerate). Stable for 24 months when properly stored.
VLDL-Receptor Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-VLDLR antibody staining is expected to be primarily localized to the cytokinetic bridge, microtubule organizing center and vesicles. There is variability in either the signal strength or the localization of signal in cytokinetic bridge and microtubule organizing center from cell to cell. Additionally, antibody labeling in the cytokinetic bridge is dependent upon phase within the cell cycle.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of VLDL-Receptor expression as measured by anti-VLDL-Receptor antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | + | – | + | ++ | – | – | + | + | + | + | – | + | – | – | + | + |
| VLDLR Variability | ++ | ++ | ++ | ++ | ++ | + | ++ | ++ | ++ | + | ++ | ++ | ++ | ++ | ++ | ++ | ++ | + | ++ | ++ |
| VLDL-Receptor General Information | |
|---|---|
| Alternate Names | |
| Very-low-density-lipoprotein receptor, VLDLR | |
| Molecular Weight | |
| 143-161kDa | |
| Chromosomal Location | |
| 9p24 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | VLDLR |
| Entrez Gene ID | 7436 |
| Ensemble Gene ID | ENSG00000147852 |
| RefSeq Protein Accession(s) | NP_001309155, NP_001018066, NP_003374, NP_001309154 |
| RefSeq mRNA Accession(s) | NM_001018056, NM_001322225, XR_001746373, NM_003383 NM_001322226 |
| RefSeq Genomic Accession(s) | NC_018920, NC_000009, NG_012741 |
| UniProt ID(s) | Q5VVF5, P98155 |
| UniGene ID(s) | Q5VVF5, P98155 |
| HGNC ID(s) | 12698 |
| Cosmic ID(s) | VLDLR |
| KEGG Gene ID(s) | hsa:7436 |
| PharmGKB ID(s) | PA37317 |
| General Description of VLDL-Receptor. | |
| VLDLR (very low density lipoprotein receptor) is a member of the LDL receptor gene family, which includes LDL receptor, LRP, megalin, VLDLR and ApoER2. The LDL receptor family is characterized by a cluster of cysteine-rich class A repeats, epidermal growth factor (EGF)-like repeats, YWTD repeats and an O-linked sugar domain. VLDLR associates with RAP (receptor associated protein) during receptor folding, and RAP facilitates the secretion of the extracellular region of VLDLR. VLDLR is thought to mediate the interaction of extracellular Reelin and cytosolic mDab1 (mammalian disabled protein), which activates a tyrosine kinase. This pathway regulates the migration of neurons along the radial glial fiber network during brain development. | |
Limitations and Warranty
enQuire Bio’s VLDL-Receptor Anti-Human Monoclonal is available for Research Use Only. This antibody is guaranteed to work for a period of two years when properly stored.
There are no reviews yet.